A recently published Cureus article examining medical cannabis as a potential adjunct strategy for reducing opioid use among chronic pain patients was featured in Pain News Network, a nonprofit online news service focused on chronic pain and pain management.
The article, “Medical Cannabis as an Opiate Alternative: A Prospective Observational Cohort Study,” was published in Cureus on April 17, 2026, by Franklin E. Caldera, Zachary Caldera, Frances Shofer, Benjamin Abramoff, David Lenrow, Stephen Hampton, Adrian Popescu, and Timothy Dillingham. The study followed 29 chronic pain patients who were using opioid medication, wanted to reduce or discontinue opioid use, and identified cost as a major barrier to accessing medical cannabis.
In the study, participants received access to cost-subsidized medical cannabis products and were started on individualized opioid tapering plans. Researchers monitored daily opioid use, pain scores, and pain-related quality-of-life measures over a five-month period. The study found that average daily opioid use decreased from 46.8 morphine milligram equivalents at baseline to 16.2 morphine milligram equivalents after one month, with the reduction maintained during follow-up. Pain scores also decreased, and seven participants were able to completely discontinue opioid therapy by the end of the study.
The findings are especially relevant because cost remains a barrier for many patients considering medical cannabis. In its coverage, Pain News Network highlighted the out-of-pocket expenses associated with medical marijuana, including product costs, physician consultations, and state medical marijuana cards, noting that these costs can put medical cannabis out of reach for some chronic pain patients.
As the Cureus authors note, the study has important limitations, including its small sample size, single-site design, lack of a control group, and variability in cannabis product selection and dosing. The findings should therefore be interpreted as preliminary and not as evidence that medical cannabis is appropriate for every patient with chronic pain. However, the study contributes to an ongoing conversation about pain management, opioid reduction, access barriers, and the need for additional research using longer follow-up periods and standardized cannabis formulations.
For Cureus authors and readers, this media coverage also shows how peer-reviewed research can reach audiences beyond the journal itself. When medical research is accessible, discoverable, and connected to timely public health conversations, it has greater potential to inform clinicians, patients, policymakers, and the broader healthcare community.
Join the discussion
Add your email, first name, and last name to leave a comment.